Showing results (861-870 of 930) with videos related to

Sort By:
Pageof 93
Ejhaem|December 17, 2025
Gain/Amplification 17p as a Potential Favorable Prognostic Factor in Multiple Myeloma: A Real-World Settings Retrospective StudyTeng Wang, Siyuan Cui, Jingyi Wang, et al.
Ejhaem|January 21, 2026
Innate Immune Cell Infiltration Induced by Polatuzumab Vedotin Contributes to the Antitumor Effect in Mouse ModelsMayu Tomita, Natsumi Kawasaki, Keigo Yorozu, et al.
Ejhaem|December 15, 2025
Ruxolitinib and Hydroxycarbamide Are the Most Efficient Drugs to Reduce Aquagenic Pruritus Intensity in a Real-Word Cohort of Patients With Myeloproliferative NeoplasmsChristelle Le Gall-Ianotto, Lanig Civi, Brigitte Pan-Petesch, et al.
Ejhaem|December 12, 2025
Adult Acute Myeloid Leukaemia With <i>DDX3X::MLLT10</i>: A Rare Entity With Significant Unmet Clinical NeedsJun Yen Ng, Arun Sr, Maansi Joshi, et al.
Ejhaem|November 6, 2025
Machine Learning-Based Detection of HbS and HbC Carriers in the UK General PopulationFrederik Christensen, Deniz Kenan Kılıç, Alexander Djupnes Fuglkjær, et al.
Ejhaem|October 29, 2025
Common Themes and Uncertainties in Management of Secondary Polycythaemia: An International Clinician Survey of PracticePhillip Lr Nicolson, Midhat Asif, Richard J Buka, et al.
Ejhaem|September 15, 2025
Use of Hospital-at-Home Services for Injectable Chemotherapy for Patients With Multiple Myeloma in France in 2019 and 2020: A Real-World Nationwide Study Based on the French Hospital Discharge DatabaseLaure Vincent, Anne-Sophie Jannot, Hakima Mechiche, et al.
Ejhaem|May 14, 2025
Assessment of the Tolerability and Optimal Dosing of the Combination of Brentuximab Vedotin and Lenalidomide in Patients With Relapsed or Refractory T-cell Lymphoma: Results of a Single-centre Phase 1 Dose-escalation StudyCarrie van der Weyden, Mathias Bressel, Amit Khot, et al.
Ejhaem|May 20, 2025
Correction to "Real-World Practitioner Perceptions of CARTITUDE-4 Results for Patients With Previously Treated Multiple Myeloma"
Ejhaem|May 9, 2025
Treatment of an Indolent T-Cell Lymphoma of the Gastrointestinal Tract Harboring <i>STAT3::JAK2</i> With Jakafi (Ruxolitinib) With Significant Clinical ImprovementsXi Cao, Carolyn Mulroney, Huan-You Wang
Pageof 93